Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
ARVN001 was developed by Clearside and is currently being sold in the United States by Bausch + Lomb as XIPERE. Image credit: ©Pixels Hunter – stock.adobe.com
Arctic Vision has signed a new commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. for ARVN001 for the treatment of uveitic macular oedema (UME) and certain other ophthalmic indications under development.
According to a press release1 issued in association with Clearside Biomedical, under the terms and conditions of the agreement Arctic Vision has granted the rights of ARVN001 to Santen to commercialise the product candidate in China excluding Taiwan, Hong Kong and Macau. ARVN001 is a triamcinolone acetonide injectable suspension for suprachoroidal use, was developed by Clearside and is currently being sold in the United States by Bausch + Lomb as XIPERE.
George Lasezkay, PharmD, JD, President and Chief Executive Officer of Clearside, noted the company’s continued collaboration in an effort to bring this treatment to those patients in need of it around the globe. In the press release, he said, “This commercialization agreement provides additional strategic validation of our suprachoroidal delivery platform by another global pharmaceutical company. Our innovative drug delivery platform is now being used in commercial products and promising clinical development programs by Santen, Bausch + Lomb, AbbVie Inc., REGENXBIO Inc., Aura Biosciences, Inc., and BioCryst Pharmaceuticals, Inc.”
Lasezkay continued, saying, “Arctic Vision has made excellent progress advancing our product in the Asia-Pacific region with a positive Phase 3 trial, regulatory review ongoing in Australia and Singapore, and a pending submission for approval in China. Leveraging the global capabilities of Santen to commercialise ARVN001, if approved in China, is another successful step to bring this important treatment to UME patients in the Asia-Pacific region. This partnership will enable training and use of our SCS Microinjector® in major international markets, which provides benefit to Clearside and all of our partners in driving the adoption of SCS delivery. Recently published data from a survey of US-based retinal specialists indicated that the suprachoroidal injection technique was easy to learn and resulted in favorable patient outcomes consistent with clinical trial data.”
Arctic Vision is a specialty ophthalmology company based in China that has the exclusive license for the commercialisation and development of ARVN001 in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.
In July 2024, Arctic Vision announced positive topline results from its Phase 3 clinical trial in China in UME. They also have New Drug Applications for ARVN001 under review in Australia and Singapore for the treatment of UME. In addition, Arctic Vision is developing ARVN001 for other ocular retinal diseases, including diabetic macular oedema.
